KOSDAQBiotech & Pharma180400

Dx & Vx

₩2,365▲ 1.07%2026-10-02 close

Market Cap

₩232.8B

Turnover

₩75,168,940

Volume

30,000 shares

Shares out.

98.4M

PER

—

PBR

2.8×

EPS

-₩256

Dividend Yield

0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close

Report overview

DXVX Seeks Rebound After Capital Injection

Having averted complete capital impairment through a large rights offering, DXVX is seeking earnings improvement on the back of multiple technology licensing deals and its drug and diagnostics pipeline.

1
2025 revenue fell to KRW 29.36 billion, declining for a third straight year, while the operating loss widened to KRW 24.32 billion.
2
A roughly KRW 100 billion third-party rights offering to the largest shareholder in December 2025 resolved capital impairment concerns, improving the debt ratio from 342.4% (2024) to 61.7% (2025).
3
The company has signed a series of global technology licensing deals covering its mRNA cancer vaccine and drug-delivery platform (ACP).
4
OVM-200, the cancer vaccine of UK subsidiary Oxford VacMedix, met both primary and secondary endpoints in its Phase 1 trial.
5
The company remains designated as an administrative issue, and listing-related risks such as a recurrence of the pre-tax loss threshold persist.

Business structure

DXVX is a bio-healthcare company operating three business segments — medical diagnostics, healthcare, and drug development — providing solutions based on genomic diagnostics, in-vitro diagnostics, and microbiome technology.

Founded in 2001 and listed on KOSDAQ in 2015, the company expanded its business scope through the acquisitions of Korea BioPharm in 2022 and Ebixgen in 2023.

The healthcare segment, operated through subsidiary Korea BioPharm, produces maternal and infant products under its own brand ofmom, including formula and supplements, and expanded its domestic consumer reach through placement at discount retailer Daiso in the first half of the year while also pursuing exports, largely to China.

The drug development segment holds a diverse pipeline including an mRNA cancer vaccine, a room-temperature-stable long-term mRNA vaccine platform, an oral obesity treatment, and the OVM-200 cancer vaccine.

Subsidiary Ebixgen, in which DXVX holds a 66.2% stake, possesses a next-generation drug-delivery platform (ACP) technology applicable broadly from small-molecule compounds to peptides, RNA, and antibodies.

UK subsidiary Oxford VacMedix is developing the OVM-200 cancer vaccine and has conducted clinical trials in patients with advanced non-small-cell lung cancer, ovarian cancer, and prostate cancer.

The largest shareholder is Chairman Lim Chong-yoon of Korea Group, who became the controlling shareholder in 2021, renamed the company from Cancerrop to DXVX, and has since expanded its business structure from a diagnostics focus toward healthcare and drug development.

In the diagnostics segment, companies such as Bioneer, Macrogen, Access Bio, Theragen Etex, and LabGenomics are classified as comparable peers.

Earnings trend

Quarterly revenue · Operating profit

₩8.7B-₩7.9B25Q2₩5.6B-₩6.8B25Q3₩7.6B-₩2.9B25Q4₩6.7B-₩5.3B26Q1₩6.4B-₩6B26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩32.2B₩2.6B2022₩46.7B-₩12.1B2023₩33.9B-₩21.6B2024₩29.4B-₩24.3B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	₩8.7B	-₩7.9B	−91.2%
2025Q3	₩5.6B	-₩6.8B	−121.0%
2025Q4	₩7.6B	-₩2.9B	−39.0%
2026Q1	₩6.7B	-₩5.3B	−78.9%
2026Q2	₩6.4B	-₩6B	−94.2%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	₩32.2B	₩2.6B	-₩1B	8.2%	−2.9%	150.2%
2023	₩46.7B	-₩12.1B	-₩27.5B	−25.9%	−129.8%	247.0%
2024	₩33.9B	-₩21.6B	-₩47B	−63.6%	−336.7%	342.4%
2025	₩29.4B	-₩24.3B	-₩29B	−82.8%	−30.9%	61.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-22

Earnings analysis

DXVX's consolidated revenue rose from KRW 32.18 billion in 2022 to KRW 46.75 billion in 2023, but then declined for two consecutive years to KRW 33.95 billion in 2024 and KRW 29.36 billion in 2025.

Operating profit swung from a KRW 2.63 billion gain in 2022 back into losses of KRW 12.08 billion in 2023, KRW 21.60 billion in 2024, and KRW 24.32 billion in 2025, with the operating margin deteriorating from 8.2% in 2022 to negative 82.8% in 2025.

The net loss attributable to owners widened sharply from KRW 27.48 billion in 2023 to KRW 47.03 billion in 2024, before narrowing slightly to KRW 29.04 billion in 2025.

On a quarterly basis, revenue fell sharply from KRW 8.66 billion in the second quarter of 2025 to KRW 5.61 billion in the third quarter, then fluctuated in the range of roughly KRW 6-7.5 billion through the fourth quarter of 2025 and the first two quarters of 2026.

The quarterly operating loss widened to KRW 6.79 billion in the third quarter of 2025, narrowed to KRW 2.94 billion in the fourth quarter, then widened again to KRW 5.25 billion and KRW 6.04 billion in the first and second quarters of 2026, respectively.

The combined net loss attributable to owners over the most recent four quarters (Q3 2025 through Q2 2026) reached KRW 25.22 billion, underscoring the persistence of losses.

On the balance sheet, total equity fell to negative KRW 3.2 billion at the end of the third quarter of 2025, triggering a state of complete capital impairment, before the company reversed the situation through a third-party rights offering involving the largest shareholder in December.

As a result, the debt ratio, which had climbed to 247.0% in 2023 and 342.4% in 2024, improved sharply to 61.7% in 2025, and while operating cash flow remained negative (KRW 18.85 billion outflow in 2025), balance-sheet risk has eased.

Industry analysis

In the domestic genomic and molecular diagnostics sector, companies such as Bioneer, Macrogen, Access Bio, Theragen Etex, and LabGenomics are classified as comparable peers, and DXVX represents a case that started in diagnostics before expanding into healthcare and drug development.

The maternal and infant health-supplement and formula market is pursuing growth through expanded distribution channels such as Daiso alongside overseas channels including China, even amid Korea's low birth rate.

In the drug development segment, out-licensing discussions with global pharmaceutical and biotech companies around mRNA vaccine platforms, cancer vaccines, and drug-delivery platforms are a broad industry theme.

Global partnering events such as BIO USA serve as the world's largest biotechnology business events, drawing more than 20,000 participants from pharmaceutical companies and investment institutions worldwide, providing a forum for discussions on technology transfer, joint development, and strategic investment.

The oral obesity treatment (GLP-1 class) market is an area where large global pharmaceutical companies compete intensely, presenting a relatively high entry barrier for later entrants.

Novel technologies such as room-temperature-stable mRNA platforms are drawing interest from the vaccine and RNA therapeutics industry for their potential to reduce reliance on cold-chain distribution.

Smaller domestic biotech firms generally have limited internal clinical and commercialization capacity, leading many to adopt a business model of out-licensing early-stage pipelines to larger partners to manage financial risk.

Outlook

The company expects earnings to improve as its drug development and healthcare business results materialize more fully.

Management itself acknowledges that while it currently operates diagnostics, healthcare, and drug development businesses, results have deteriorated each year, and it is seeking a turnaround through leadership realignment and strengthened business development.

The AI-driven drug toxicity prediction platform 'AI TOX,' built on clinical genomic big data, is planned to be advanced in stages with commercial service targeted for launch from the fourth quarter onward.

The company was selected as the lead institution for a Ministry of Health and Welfare project on antiviral treatment development in preparation for 'Disease X,' under which it will receive government support for up to four years (2+2 years) to conduct research on candidate substance discovery and clinical IND approval.

Its room-temperature, ultra-long-term-storage mRNA platform, following a 2025 material transfer agreement (MTA) with a global healthcare company, signed a second MTA in January 2026 with a European RNA technology platform biotech, opening the possibility of moving into term-sheet and definitive contract negotiations after in-depth evaluation.

At BIO USA in June, the company held partnering meetings with more than 40 global pharmaceutical and biotech companies, broadening the base for overseas licensing discussions.

To address legal and regulatory risks associated with overseas business expansion, the company is in the process of bringing in a lawyer as a candidate for co-CEO, a move interpreted as reinforcing its execution capability for licensing contracts and business development.

Valuation

PER

—

PBR

2.8×

ROE

-59.0%

EPS

-₩256

BPS

₩837

Dividend per share

₩0

DXVX has posted net losses for multiple consecutive years, including the most recent four quarters, making profit-based metrics such as the price-to-earnings ratio difficult to compute in a meaningful way.

Following the large rights offering in December 2025 that substantially rebuilt total equity, the state of complete capital impairment was resolved, but the shares still tend to trade at a premium relative to net asset value.

Dividends have not been paid in recent years, making dividend-based comparisons within the industry difficult.

Looking at the historical earnings trajectory, operating profit swung from a gain in 2022 to losses from 2023 onward that widened before narrowing somewhat in 2025, suggesting a partial directional improvement, though it should be kept distinct that resolving capital impairment reflects funding-side stabilization rather than an immediate recovery in core business profitability.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-22

Bull factors

Successive Global Licensing Deals

In July 2025, the company signed a joint development and licensing deal worth roughly KRW 300 billion for its mRNA cancer vaccine with a US biotech, and in August its subsidiary Ebixgen transferred its ACP drug-delivery platform technology to a US biotech company in a deal worth about KRW 500 billion.

In January 2026, it signed a second material transfer agreement (MTA) for its room-temperature, long-term-storage mRNA platform with a European RNA technology biotech.

While most payments are structured as milestones and sales royalties, achieving multiple global partnering outcomes within a short period signals external validation of pipeline value.

Resolved Capital Impairment and Improved Balance Sheet

Having fallen into complete capital impairment in the third quarter of 2025, DXVX rebuilt its capital base through a roughly KRW 100 billion third-party rights offering to the largest shareholder in December.

The fact that the largest shareholder participated at a price 20% above the reference price was interpreted as a sign of commitment to responsible management. As a result, the debt ratio fell sharply from 342.4% in 2024 to 61.7% in 2025, improving financial soundness.

Diversified Pipeline and Government Project

OVM-200, the cancer vaccine of UK subsidiary Oxford VacMedix, met all primary and secondary endpoints in its Phase 1 trial, including safety, immune response, and optimal dose selection.

The company was selected as the lead institution for a Ministry of Health and Welfare project on antiviral treatment development for 'Disease X' preparedness, receiving government support for up to four years.

Its AI-based drug toxicity prediction platform 'AI TOX' is also under development with commercialization targeted from the fourth quarter, diversifying the pipeline across diagnostics, vaccines, therapeutics, and AI platforms.

Bear factors

Shrinking Core Revenue and Persistent Losses

Revenue declined for two straight years, from KRW 46.75 billion in 2023 to KRW 29.36 billion in 2025, while the operating loss widened from KRW 12.08 billion to KRW 24.32 billion over the same period. Losses continued into the first half of 2026, with quarterly operating losses of KRW 5.25 billion and KRW 6.04 billion.

The company itself has acknowledged that results have deteriorated each year, and until licensing milestones actually convert into cash inflows, a recovery in core business profitability remains difficult to confirm.

Share Dilution from the Large Rights Offering

The December 2025 rights offering roughly doubled total shares outstanding, from about 49.21 million to about 98.43 million shares. Since the entire offering was allotted to the single largest shareholder, existing minority shareholders' ownership percentage was relatively diluted.

If additional funding is needed in the future, the possibility of a similar offering being conducted again cannot be ruled out.

Dependence on Milestone-Based Licensing

The mRNA cancer vaccine licensing deal is structured so that the partner pays roughly KRW 300 billion in total through development-stage milestones plus post-commercialization sales milestones, with profit-sharing after commercialization determined separately.

This means that even where deal sizes are large, actual cash inflow depends heavily on the success of clinical and development milestones.

Many of these contracts are structured around preclinical and clinical milestones rather than upfront payments, making it difficult for them to directly improve the balance sheet in the near term.

Risk factors

Governance and Funding Risk

Largest shareholder Lim Chong-yoon previously borrowed funds against Hanmi Science shares as collateral to finance participation in DXVX's rights offering, and has previously faced forced share sales after failing to repay a stock-collateralized loan.

If the collateralized Hanmi Science share price were to decline, additional collateral calls or forced liquidation could occur, meaning the largest shareholder's financial condition could also affect DXVX's future capital-raising capacity.

Listing Maintenance Risk

DXVX has been designated as an administrative issue after incurring pre-tax losses exceeding 50% of equity in at least two of the past three years.

If it meets this loss threshold again in a future fiscal year while under this designation, it could become subject to a listing eligibility review, meaning continued capital reinforcement and loss management are necessary.

Clinical and Commercialization Uncertainty

Key pipeline assets such as OVM-200 remain at the Phase 1 stage and require multiple further clinical stages before commercialization. Licensing deals are also weighted more toward milestones than upfront payments, making the actual timing of monetization uncertain.

The ongoing process of bringing in a legal professional as co-CEO to address contract and regulatory risks from overseas business expansion, conversely, underscores the considerable legal and regulatory complexity involved in that expansion.

What to watch next

Around November 2026
Check the Q3 2026 quarterly report for signs of revenue recovery and any narrowing of the operating loss.
Q4 2026
Check whether the 'AI TOX' drug toxicity prediction platform launches commercially as planned and whether it contributes early-stage revenue.
Second half of 2026
Check whether an extraordinary shareholders' meeting is held and finalizes the appointment of the lawyer candidate as co-CEO.
Upon any additional licensing announcement
Check whether the material transfer agreement with the European RNA biotech progresses to a term sheet or definitive contract, and review the deal terms including upfront payments versus milestone structure.
Around March 2027 annual report filing
Check whether the pre-tax loss threshold is triggered again for fiscal year 2026 and whether the administrative-issue designation is lifted.

Overall view

DXVX has experienced years of declining revenue and widening operating losses across its diagnostics, healthcare, and drug development businesses, and fell into complete capital impairment in the third quarter of 2025.

A December rights offering involving the largest shareholder rebuilt capital and sharply lowered the debt ratio, but this represents funding-side stabilization rather than a recovery in core business profitability.

At the same time, the company has signed a series of global licensing deals covering its mRNA cancer vaccine, drug-delivery platform, and room-temperature mRNA platform, while also diversifying its pipeline through Phase 1 results for OVM-200 and selection for a government project.

However, most of these deals are structured around milestones and royalties, leaving timing and uncertainty around actual cash inflows, and governance and listing-related variables — including the administrative-issue designation and the largest shareholder's personal funding risk — also warrant continued attention.

Key variables to monitor going forward include upcoming quarterly results, the commercialization of AI TOX, any additional licensing deals, and whether the pre-tax loss threshold recurs.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.